Yeast Enzyme Aids Human Cell Mitochondrial Repair: A Breakthrough in Understanding and Treating Mitochondrial Disorders
The human body is a complex system, and one of its most critical components is the mitochondria, the powerhouses of our cells. Mitochondria play a vital role in generating the energy required for life, and they also contribute to fundamental processes like DNA synthesis. However, when mitochondrial respiration fails, as seen in mitochondrial diseases and certain types of cancer, cells struggle to proliferate normally. A recent study published in Nature Metabolism has made a groundbreaking discovery that could revolutionize our understanding and treatment of these conditions.
The study, led by José Antonio Enríquez of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Spanish network for research into frailty and healthy aging (CIBERFES), has experimentally uncoupled nucleotide synthesis from mitochondrial activity using ScURA, a yeast-derived genetic tool. This tool has opened up new avenues for exploring cellular metabolism and its implications for human health.
The research team, which also included scientists from the University of Cologne (Germany), the University of Valladolid (UVa), and the CSIC–UVa Institute of Biology and Molecular Genetics, made a fascinating discovery. They identified a yeast enzyme that can sustain nucleotide synthesis independently of mitochondrial respiration. This enzyme, named ScURA, uses fumarate, a metabolite derived from nutrients, instead of oxygen. By extracting the gene encoding this enzyme from yeast and inserting it into human cells, the team achieved remarkable results.
The patient-derived cells used in the study, which cannot grow in standard laboratory conditions due to their unique nutritional requirements, showed a significant improvement when ScURA was introduced. These cells were able to grow under normal conditions, just like healthy cells. The authors explained that the yeast gene enabled the cells to 'learn' a new way of building DNA.
One of the most striking findings was that human cells expressing ScURA continued to produce DNA and RNA even when the mitochondrial respiratory chain was blocked. This is a crucial discovery because it highlights the potential of ScURA as a therapeutic tool. Unlike the equivalent human enzyme, which is physically linked to mitochondria, the yeast version works independently and uses an alternative metabolic pathway.
The team also found that ScURA helped cells use their nutrients more efficiently without disrupting other essential cellular functions. This is a significant step towards the goal of improving the lives of people with mitochondrial disorders. Lead author José Antonio Enríquez emphasized the importance of this discovery, stating that it demonstrates the potential to sustain cell proliferation even when mitochondrial respiration fails.
One of the most significant implications of this study is that ScURA-modified cells can grow without the need for uridine supplementation, a common strategy used in laboratories to compensate for mitochondrial defects. This breakthrough allows for a clearer understanding of the direct effects of mitochondrial dysfunction on nucleotide synthesis, as first author Andrea Curtabbi explained.
The study also has profound implications for rare diseases and cancer. Mitochondrial diseases are severe and often untreatable, but when ScURA was inserted into these cells, they proliferated under standard conditions, just like healthy cells. This highlights the potential of ScURA as a therapeutic tool for these diseases. Moreover, the enzyme's ability to boost nutrient efficiency without altering other cellular functions makes it a valuable experimental tool.
The authors further emphasize the potential of ScURA for clarifying the mitochondrial contributions to rare diseases and cancer. Identifying the metabolic processes that become limiting when mitochondrial respiration fails is crucial for designing precise therapeutic strategies, according to Enríquez. The team plans to expand their findings to other disease models and optimize this approach for preclinical research.
The project was funded by several organizations, including the Spanish Ministry of Science and Innovation, the Human Frontier Science Program, the Leducq Foundation, and the Instituto de Salud Carlos III–CIBERFES. The CNIC, directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and translating its findings into patient benefits. The center has been recognized as a Severo Ochoa center of excellence, further highlighting its significance in the scientific community.
